Q2, Dr Reddy

Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
(Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market,
Dr. Reddy's Laboratories Ltd reports Rs. 1255.3 crores consolidated PAT in Q2 FY2025
The Board of Directors of Dr. Reddys Laboratories Limited, at its meeting held today have approved the financial results of the company for the period ended September 30, 2024 - Q2 FY2024-25, H1 FY2024-25.
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Lack of strong launch pipeline keep brokerages neutral over Dr Reddy's Labs
Despite reporting decent earnings for the July-September quarter, brokerages continue to maintain their neutral stance over ...
Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets
With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...
Daily19h
Dr Reddy's Labs recalls over 3 lakh bottles of Cinacalcet tablets in US over manufacturing issues
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets, a medication used for treatment of high ...
Benzinga.com16h
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Global generics revenue grew 17% YoY, driven by sales volume gains and new launches. Dr. Reddy’s Laboratories Ltd RDY reported Tuesday a second-quarter 2025 net income of $160 million, down from ...
Stocks in news: Titan, Dr Reddy's Labs, NTPC, Tata Steel, Infosys, GAIL, Hero Moto & Mankind
Stocks including Titan Company, Dr Reddy's Labs, NTPC, Tata Steel, Infosys, GAIL (India), Hero Motocorp, Mankind Pharma and ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
cnbctv185h
Healthcare major Dr Reddy's Q2 net profit falls, revenue gains momentum
Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
Hosted on MSN1d
Q2 Results Today: Titan, Dr Reddy's, GAIL, Oil India, PolicyBazaar, Mazgon Dock, Waaree Renewable and others to report quarterly earnings on Nov 05
Titan, GAIL, PolicyBazaar, Dr Reddy's, Oil India, Mankind Pharma, Mazagon Dock are among the 64 companies that will report ...